Jeevan Scientific Technology Ltd

Jeevan Scientific Technology Ltd., a clinical contract research organisation, delivered a remarkable 54.04% quarter-on-quarter revenue surge in Q3 FY26, posting net sales of ₹19.07 crores against ₹12.38 crores in Q2 FY26. However, the company's consolidated net profit of ₹1.42 crores, whilst positive, reflects ongoing profitability challenges that have plagued the micro-cap healthcare services firm. With a market capitalisation of ₹110.00 crores, the stock traded at ₹70.01 on February 11, 2026, up 1.10% from the previous close.

Jeevan Scientific Technology Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jeevan Scientific Technology Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jeevan Scientific Technology Ltd, a key player in the Healthcare Services sector, reached a significant milestone today by hitting a new 52-week high of Rs.76.99. This achievement marks a continuation of the stock’s robust upward momentum, reflecting sustained gains over recent sessions and outperforming its sector peers.

Jeevan Scientific Technology Ltd, a key player in the Healthcare Services sector, reached a significant milestone today by hitting a new 52-week high of Rs.75.02. This achievement underscores the stock’s robust momentum, driven by sustained gains over recent sessions and strong market positioning.

Jeevan Scientific Technology Ltd, a key player in the Healthcare Services sector, reached a significant milestone today by hitting a new 52-week high of Rs.71.45. This achievement marks a continuation of the stock’s strong upward momentum, reflecting sustained gains over recent sessions and outperforming its sector peers.

Jeevan Scientific Technology Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Jeevan Scientific Technology Ltd, a key player in the Healthcare Services sector, reached a significant milestone on 5 Jan 2026 by hitting a new 52-week high of Rs.68.25. This achievement marks a notable uptrend for the stock, reflecting sustained momentum amid a mixed market backdrop.

Jeevan Scientific Technology Ltd, a key player in the Healthcare Services sector, reached a significant milestone today by hitting a new 52-week high of Rs.67. This achievement marks a continuation of the stock’s strong upward momentum, reflecting sustained gains over recent sessions and robust market positioning.

Jeevan Scientific Technology Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 December 2025, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Jeevan Scienti., a microcap player in the Healthcare Services sector, has experienced a revision in its market evaluation reflecting nuanced changes across key financial and technical parameters. Despite persistent challenges in profitability and valuation, recent market activity and technical indicators have contributed to a shift in the company’s overall assessment.

Jeevan Scientific Technology has shown improved financial stability in its latest quarter, with operating cash flow reaching Rs 10.07 crore. However, challenges persist, including a decline in profit after tax and low inventory and debtors turnover ratios. The company has outperformed the Sensex in recent market performance.

Jeevan Scientific Technology Ltd., a clinical contract research organisation, reported a consolidated net loss of ₹0.09 crores in Q2 FY26, marking a dramatic reversal from the ₹0.24 crores profit recorded in the same quarter last year. The micro-cap healthcare services company, with a market capitalisation of ₹98.17 crores, saw its stock trade at ₹62.00 following the results, reflecting a modest 0.26% gain as investors grappled with the company's persistent profitability challenges despite a sequential improvement in revenue.